Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PI-88 adjuvant therapy after resection of hepatocellular carcinoma
CTR20131019Phase 3Active
- Sponsor
- Genea Biocells
- Start
- Mar 2015
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Muparfostat in hepatocellular carcinoma (HCC), sponsored by Genea Biocells. Started Mar 2015; status: active.
02
Drugs
Muparfostat
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20131019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131019.